摘要:
The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diones and their physiologically acceptable salts and physiologically functional derivatives. The invention relates therefore to the compounds of formula (I) wherein the residues are defined as indicated, to the physiologically salts thereof and to methods for producing the same. The inventive compounds are suited for use, for example, as antidiabetic agents.
摘要:
The invention relates to a simple continuous test for identifying structures that favour the arrangement of aromatics for charge-transfer complexes, e.g. complex phospholipid/lipid structures (bilayer, monolayer, aggregates, micelles), using synthetic fluorescence-marked acylglycerides, and to their use for determining the activity of lipases/lipase inhibitors, to a monoacylglyceride for use in this test and to a method for producing the same, to the substrate obtained therefrom and to a method for producing said substrate.
摘要:
The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl (C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10 alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.
摘要:
The invention relates to compounds of formula (I) wherein the radicals have the cited designations, and to the physiologically compatible salts thereof. Said compounds are suitable, for example, as medicaments for reducing blood sugar levels and for the prevention and treatment of diabetes.
摘要:
The aim of the invention is to provide compounds having a therapeutic blood-sugar decreasing effect. Said compounds are suitable especially for the prevention and treatment of pancreatic diabetes. To this end, the invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 independently represent H, F, Cl, Br, J, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-alkyl, O-(C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O-(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O-(C3-C8)-cycloalkenyl, (C2-C6)-alkinyl, aryl, O-aryl, (C1-C8)alkylene-aryl, O-(C1-C8)-alkylene-aryl, S-aryl, CO-NH(C1-C6)-alkyl, N((C1-C6)-alkyl)2, NH-SO2-CH3, SO2-CH3, COOH, COO-(C1-C6)-alkyl, or CO-N((C1-C6)-alkyl)2; R6 represents H, (C1-C6)-alkyl; A represents a bond, -CH2-, -NH-, -CH2-O-, -S-, -CH2-CH2-, or -CH(CH3)-; B represents NH, NH(C1-C4)-alkyl, or NH(CO); and D represents phenyl or a heterocycle. The invention also relates to the physiologically compatible salts of said compounds.
摘要:
The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. Formula (I) These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK15 30 (glycogen synthase kinase-3ß).
摘要:
The present invention refers to a method for identification of a chemical compound which modulates the activity of mammalian GPI-PLC wherein a] a mammalian cell is incubated with glimepiride; b] hcDlGs of the cells of a] are prepared; c] the hcDlGs from b] are incubated with a chemical compound; d] the activity of the GPI-PLC from the hcDlGs of c] is determined.
摘要:
The aim of the invention is to provide compounds having a therapeutic blood-sugar decreasing effect. Said compounds are suitable especially for the prevention and treatment of pancreatic diabetes. To this end, the invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 independently represent H, F, Cl, Br, J, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-alkyl, O-(C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O-(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O-(C3-C8)-cycloalkenyl, (C2-C6)-alkinyl, aryl, O-aryl, (C1-C8)alkylene-aryl, O-(C1-C8)-alkylene-aryl, S-aryl, CO-NH(C1-C6)-alkyl, N((C1-C6)-alkyl)2, NH-SO2-CH3, SO2-CH3, COOH, COO-(C1-C6)-alkyl, or CO-N((C1-C6)-alkyl)2; R6 represents H, (C1-C6)-alkyl; A represents a bond, -CH2-, -NH-, -CH2-O-, -S-, -CH2-CH2-, or -CH(CH3)-; B represents NH, NH(C1-C4)-alkyl, or NH(CO); and D represents phenyl or a heterocycle. The invention also relates to the physiologically compatible salts of said compounds.
摘要:
The present invention refers to a method for identification of a chemical compound which modulates the activity of mammalian GPI-PLC wherein a] a mammalian cell is incubated with glimepiride; b] hcDlGs of the cells of a] are prepared; c] the hcDlGs from b] are incubated with a chemical compound; d] the activity of the GPI-PLC from the hcDlGs of c] is determined.